Skip to main content
Premium Trial:

Request an Annual Quote

Santaris, Miragen Expand microRNA Partnership to Include Additional Targets

Premium

Santaris Pharma and Miragen Therapeutics this week announced that they have expanded their ongoing microRNA therapeutics partnership to include six additional targets.

The companies first began working together in 2010 when they signed a deal giving Miragen access to Santaris' locked nucleic acid technology to develop miRNA inhibitors against four unnamed cardiovascular disease targets (GSN 6/24/2010). As part of the arrangement, Santaris picked up an undisclosed stake in Miragen.

The newest agreement brings the number of targets against which Miragen can apply the LNA technology to ten. As with the first deal, Santaris received an upfront payment of cash and equity, and stands to receive payments based on the achievement of clinical milestones plus royalties on marketed products.

Additional terms were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.